-
NYU Dataset
Augmentation of Parasympathetic Signaling with Pyridostigmine in Heart Failure
- Alternate Title(s)
- APP-HF
- Authors
- Randal GoldbergLucy Norcliffe-KauffmanIkoa Jeschke-LopezYu Guo8 more author(s)...
- Description
This dataset was collected during a prospective phase 2 double-blind randomized placebo-controlled a dose-finding clinical trial to compare the effects of three ascending doses of pyridostigmine (15, 30, and 60 mg three times daily) vs. matching placebo on post-exercise heart rate recovery and other measures of sympathovagal balance. The study included four stages: Screening, randomization, and baseline...
- Subject
-
Chronic DiseaseHealth StatusRisk Factors
- Access Rights
- Application RequiredAuthor Approval Required